FDA clears Unicycive's OLC for hyperphosphatemia after 2025 CRL
The FDA accepted Unicycive's resubmitted NDA and set a June 29, 2026 PDUFA date a year after a manufacturing-related complete response letter forced the restart.
Executive Summary
- The FDA accepted Unicycive Therapeutics' resubmitted application for its oral phosphate binder and set a mid-2026 target action date, restarting a review that had been derailed by a manufacturing-site finding rather than a clinical or safety concern.
- The 2025 rejection stemmed from a cGMP inspection finding at a contract manufacturer, a fixable supply-chain issue distinct from the drug's own trial results, which the agency did not challenge.
- The drug would enter an indication that already has multiple approved phosphate binders, so its case rests on manufacturing execution and a pill-burden advantage rather than establishing a new treatment effect.
- The completed Phase 2 study behind the filing was a single-arm, open-label tolerability trial, not a controlled efficacy readout, so the regulatory record leans on safety and pharmacokinetic data rather than a head-to-head comparison.
The resubmission
The FDA determined Unicycive's resubmitted NDA for oxylanthanum carbonate (OLC) was a Class II complete response, triggering a six-month review clock and a June 29, 2026 PDUFA target action date. Unicycive Chief Executive Officer Shalabh Gupta said the company was "advancing our commercial preparation activities in anticipation of a potential launch of OLC later this year". The filing seeks approval through the 505(b)(2) pathway, which allows a sponsor to rely in part on existing safety and efficacy data for a related compound rather than generate an entirely new dataset. UPDATEUPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New ...Jan 29, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Why the first NDA failed
The FDA issued a complete response letter on June 30, 2025 after learning that a third-party manufacturing vendor used by Unicycive's primary contract development and manufacturing organization had been cited for deficiencies during a cGMP inspection, a facility-level finding rather than a problem with OLC's clinical evidence. The company's January 2026 disclosure reiterated that the FDA "did not raise any concerns regarding OLC's preclinical, clinical, or safety data included in the original NDA submission". That distinction separates this decision from readouts where an efficacy or safety signal drives the outcome: the underlying data package was not the obstacle. Unicycive+1Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law FirmAug 14, 2025UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New ...Jan 29, 2026
The trial behind the filing
The clinical evidence supporting the NDA includes a completed, open-label, single-arm Phase 2 tolerability study of OLC in 106 adult hemodialysis patients (NCT06218290), which finished its primary completion on May 29, 2024. The trial's primary endpoint measured the incidence of treatment-related adverse events leading to drug discontinuation during a maintenance period, a tolerability and safety measure rather than a comparative efficacy endpoint. Secondary endpoints tracked pharmacokinetic parameters for lanthanum, including peak concentration and elimination half-life, alongside broader tolerability measures. The trial closed enrollment at its target of 106 patients across seven U.S. sites, and its status moved from active to completed in mid-2024 without a material shift in enrollment against target. NCT06218290A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on DialysisNCT06218290
The competitive landscape
Multiple phosphate binders are already approved for hyperphosphatemia in CKD patients on dialysis, including sevelamer carbonate, sevelamer hydrochloride, and other agents in this indication. The closest mechanism comparator identified is Keryx Biopharmaceuticals' ferric citrate, a Phase 3 program in chronic kidney disease sharing the small-molecule modality. OLC's differentiation case rests on its nanoparticle formulation, which the company says is designed to lower the pill burden required to control serum phosphorus compared with existing binders. That is a tolerability and adherence argument within an established drug class, not a claim to a new mechanism of action. UPDATEUPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New ...Jan 29, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.